Skip to main content
NCBI home page
ESMO Open logoLink to ESMO Open
. 2021 Apr 26;6(2):100097. doi: 10.1016/j.esmoop.2021.100097

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’

[ESMO Open Volume 6, Issue 2, April 2021, 100054]

C De Angelis 1, D Bruzzese 2, A Bernardo 3, E Baldini 4, L Leo 5, A Fabi 6, T Gamucci 7, P De Placido 1, F Poggio 8, S Russo 9, V Forestieri 1, R Lauria 1, I De Santo 1, R Caputo 10, D Cianniello 10, A Michelotti 11, L Del Mastro 8,12, M De Laurentiis 10, M Giuliano 1,∗, S De Placido 1, G Arpino 1
PMCID: PMC8103531  PMID: 33926709

The authors regret that at the time the article was published the following two authors were missing from the author list: R. Caputo and D. Cianniello. Both authors affiliation is the Breast Oncology Department, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. The updated author list is as follows:

C. De Angelis, D. Bruzzese, A. Bernardo, E. Baldini, L. Leo, A. Fabi, T. Gamucci, P. De Placido, F. Poggio, S. Russo, V. Forestieri, R. Lauria, I. De Santo, R. Caputo, D. Cianniello, A. Michelotti, L. Del Mastro, M. De Laurentiis, M. Giuliano, S. De Placido, G. Arpino.

The authors would like to apologise for any inconvenience caused.

RESOURCES